Korro Bio, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

78.0 k

Shareholding (Mar 2025)

FII

9.89%

Held by 35 FIIs

DII

30.3%

Held by 23 DIIs

Promoter

37.57%

What does Korro Bio, Inc. do?

22-Jun-2025

Korro Bio, Inc. is a Micro Cap company in the Pharmaceuticals & Biotechnology industry. It currently has significant negative debt equity and return on equity metrics.

Is Korro Bio, Inc. overvalued or undervalued?

20-Sep-2025

As of March 18, 2025, Korro Bio, Inc. is considered risky and overvalued due to a negative P/E ratio of -3.38, an unfavorable EV to EBITDA ratio of -2.28, and poor stock performance, including a -12.74% year-to-date return compared to a 12.22% gain for the S&P 500.

Is Korro Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Korro Bio, Inc. shows a neutral technical trend with mixed signals, including a bullish weekly MACD and bearish RSI, while underperforming the S&P 500 by 67.59% over three years.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Positive results in Jun 25

NET SALES(HY) Higher at USD 4.01 MM
NET PROFIT(HY) Higher at USD -49.16 MM
RAW MATERIAL COST(Y) Fallen by -1,781% (YoY)

Risky - No result in last 6 months

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 309 Million (Micro Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.82

Return on Equity

-999,999.00%

Price to Book

2.69

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Jun 2025)

Net Profit:

-26 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-78.14%

6 Months

-36.76%

1 Year

-81.73%

2 Years

-85.46%

3 Years

-92.04%

4 Years

-97.13%

5 Years

-99.51%

Korro Bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Korro Bio, Inc. Experiences Revision in Stock Evaluation Amid Mixed Financial Performance

Korro Bio, Inc. reported net sales of USD 4.01 million for the quarter ending June 2025, reflecting improved revenue generation and cost management. However, the company struggles with a significant operating loss and declining earnings per share. Its debtors turnover ratio indicates effective collection practices amid ongoing market challenges.

Korro Bio Forms Golden Cross, Signaling Potential Bullish Breakout Ahead

Korro Bio, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock has outperformed the S&P 500, with a notable monthly increase of 77.53%. Despite mixed technical indicators, Korro Bio's one-year performance of 47.67% highlights its strong market position and investor interest.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-32.47%

EBIT Growth (5y)

-224.81%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

EV to EBITDA

EV to Capital Employed

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

No Trend

Bearish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 22 Schemes (22.24%)

Foreign Institutions

Held by 35 Foreign Institutions (9.89%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -18.35% vs -23.86% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.00",
          "val2": "-23.40",
          "chgp": "-11.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.80",
          "val2": "-21.80",
          "chgp": "-18.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18,631.50%",
          "val2": "0.00%",
          "chgp": "-1,863.15%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -2.96% vs -40.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-88.30",
          "val2": "-80.90",
          "chgp": "-9.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-83.60",
          "val2": "-81.20",
          "chgp": "-2.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-40,471.20%",
          "val2": "0.00%",
          "chgp": "-4,047.12%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

1.50

0.00

Operating Profit (PBDIT) excl Other Income

-26.00

-23.40

-11.11%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-25.80

-21.80

-18.35%

Operating Profit Margin (Excl OI)

-18,631.50%

0.00%

-1,863.15%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -18.35% vs -23.86% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

2.30

0.00

Operating Profit (PBDIT) excl Other Income

-88.30

-80.90

-9.15%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-83.60

-81.20

-2.96%

Operating Profit Margin (Excl OI)

-40,471.20%

0.00%

-4,047.12%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -2.96% vs -40.00% in Dec 2023

All Annual Results

Company CV

About Korro Bio, Inc.

Korro Bio, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Korro Bio, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

What does Korro Bio, Inc. do?

Watch in Real-Time

Is Korro Bio, Inc. overvalued or undervalued?

Is Korro Bio, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Positive results in Jun 25

Risky - No result in last 6 months

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Korro Bio, Inc. Experiences Revision in Stock Evaluation Amid Mixed Financial Performance

Korro Bio Forms Golden Cross, Signaling Potential Bullish Breakout Ahead

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Korro Bio, Inc.

Company Coordinates